Cixutumumab-IMC-A12-DataSheet-生命科学试剂-MedChemExpress

Hotline:400-820-3792Inhibitors•ScreeningLibraries•Proteinswww.MedChemECixutumumabCat.No.:HY-P99189CASNo.:947687-12-9Synonyms:IMC-A12;NSC742460作⽤靶点:Others作⽤通路:Others储存⽅式:PleasestoretheproductundertherecommendedconditionsintheCertificateofAnalysis.BIOLOGICALACTIVITY⽣物活性Cixutumumab(IMC-A12)⼀种具有⾼亲和⼒的⼈化抗IGF-1R单克隆抗体，抑制配体依赖的受体激活和下游信号传导。Cixutumumab还介导IGF-IR的内化和降解。Cixutumumab具有⼴谱抗肿瘤活性，可⽤于肺癌、恶性肿瘤、⽩⾎病、⾮⼩细胞肺癌和前列腺癌等癌症的研究。IC50&TargetIGF-1R[1].体外研究Cixutumumab(IMC-A12)(0.01-100nM;96h)exhibitsatleast50%growthinhibitioninCHLA-9,TC-71andRh41cells[1].CellViabilityAssay[1]CellLine:CHLA-9,TC-71,Rh41cellsConcentration:0.01-100nMIncubationTime:96hResult:InhibitedCHLA-9,TC-71andRh41cellsgrowthwithIC50valuesof49.31,0.66and0.04nM,respectively.体内研究Cixutumumab(IMC-A12)(1mg/rat;i.p.;twiceweeklyfor6weeks)showsbroad-spectrumantitumoractivity,inhibitstumorgrowthofthePPTP’sinvivosolidtumorpanels[1].AnimalModel:CB17SC-Mscid-/-femalemice(solidtumorxenograftsmodel)[1].1/2MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemEDosage:1mg/ratAdministration:Intraperitonealinjection;twiceweeklyfor6weeks.Result:DemonstratedbroadantitumoractivityagainstthePPTP’sinvivosolidtumorpanels,withtheactivityprimarilybeingtumorgrowthinhibitionratherthantumorregression.REFERENCES[1].HoughtonPJ,etal.Initialtestingofamonoclonalantibody(IMC-A12)againstIGF-1RbythePediatricPreclinicalTestingProgram.PediatrBloodCancer.2010Jul1;54(7):921-6.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseonly.Tel:400-820-3792;021-5895